{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:39:13Z","timestamp":1787510353115,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023MH166"],"award-info":[{"award-number":["ZR2023MH166"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32241005"],"award-info":[{"award-number":["32241005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370173"],"award-info":[{"award-number":["82370173"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.tranon.2025.102441","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T14:49:39Z","timestamp":1749480579000},"page":"102441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms"],"prefix":"10.1016","volume":"58","author":[{"given":"Xiaodong","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexiao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wancheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tranon.2025.102441_bib0001","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5581\/1516-8484.20120035","article-title":"Molecular biology of Philadelphia-negative myeloproliferative neoplasms","volume":"34","author":"Campregher","year":"2012","journal-title":"Rev. Bras. Hematol. E Hemoter."},{"issue":"17","key":"10.1016\/j.tranon.2025.102441_bib0002","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","article-title":"The 2008 world health organization classification system for myeloproliferative neoplasms: order out of chaos","volume":"115","author":"Tefferi","year":"2009","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.tranon.2025.102441_bib0003","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2025.102441_bib0004","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102441_bib0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.tranon.2025.102441_bib0006","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tranon.2025.102441_bib0007","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.tranon.2025.102441_bib0008","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.tranon.2025.102441_bib0009","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.tranon.2025.102441_bib0010","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"issue":"11","key":"10.1016\/j.tranon.2025.102441_bib0011","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2025.102441_bib0012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.tranon.2025.102441_bib0013","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.tranon.2025.102441_bib0014","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.tranon.2025.102441_bib0015","doi-asserted-by":"crossref","unstructured":"J. Mascarenhas et al., \u201cA randomized phase 3 trial of interferon-a vs hydroxyurea in polycythemia vera and essential thrombocythemia\u201d, doi: 10.1182\/blood.2021012743.","DOI":"10.1182\/blood.2021012743"},{"issue":"4","key":"10.1016\/j.tranon.2025.102441_bib0016","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3324\/haematol.2021.280080","article-title":"Conventional interferon-\u03b1 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center","volume":"107","author":"Liu","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.tranon.2025.102441_bib0017","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"issue":"1","key":"10.1016\/j.tranon.2025.102441_bib0018","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3892\/mco.2015.652","article-title":"Determination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: retrospective analysis of 71 patients in a single institution","volume":"4","author":"Ito","year":"2016","journal-title":"Mol. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2025.102441_bib0019","first-page":"343","article-title":"Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia","volume":"33","author":"Yap","year":"2022","journal-title":"Cancer Causes Control CCC"},{"issue":"12","key":"10.1016\/j.tranon.2025.102441_bib0020","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/ajh.24578","article-title":"Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms","volume":"91","author":"Xia","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2025.102441_bib0021","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","author":"Luque Paz","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.tranon.2025.102441_bib0022","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00432-022-04067-1","article-title":"Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study","volume":"149","author":"Zhang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2025.102441_bib0023","first-page":"276","article-title":"Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated\/blast phase","volume":"44","author":"Yan","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi"},{"key":"10.1016\/j.tranon.2025.102441_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-018-0124-7","article-title":"The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia","volume":"7","author":"Yap","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102441_bib0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102441_bib0026","first-page":"163","article-title":"Molecular genetics of thrombotic myeloproliferative neoplasms: implications in precision oncology","volume":"13","author":"Chia","year":"2023","journal-title":"Diagn. Basel Switz."},{"issue":"1","key":"10.1016\/j.tranon.2025.102441_bib0027","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/asheducation-2016.1.552","article-title":"Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions","volume":"2016","author":"Shammo","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"7","key":"10.1016\/j.tranon.2025.102441_bib0028","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"19","key":"10.1016\/j.tranon.2025.102441_bib0029","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.tranon.2025.102441_bib0030","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/10428190801895360","article-title":"JAK and MPL mutations in myeloid malignancies","volume":"49","author":"Tefferi","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"25","key":"10.1016\/j.tranon.2025.102441_bib0031","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.tranon.2025.102441_bib0032","doi-asserted-by":"crossref","first-page":"e0035","DOI":"10.5041\/RMMJ.10169","article-title":"Calreticulin mutations in myeloproliferative neoplasms","volume":"5","author":"Lavi","year":"2014","journal-title":"Rambam Maimonides Med. J."},{"issue":"10","key":"10.1016\/j.tranon.2025.102441_bib0033","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.tranon.2025.102441_bib0034","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2014-01-550434","article-title":"CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.tranon.2025.102441_bib0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40291-012-0006-3","article-title":"Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms","volume":"16","author":"Tibes","year":"2012","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.tranon.2025.102441_bib0036","article-title":"Case report: application of targeted NGS for the detection of non-canonical driver variants in MPN","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.tranon.2025.102441_bib0037","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/leu.2010.299","article-title":"Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms","volume":"25","author":"Schnittger","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.tranon.2025.102441_bib0038","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.23139","article-title":"The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms","volume":"62","author":"Kaseb","year":"2023","journal-title":"Genes. Chromosomes Cancer"},{"issue":"7","key":"10.1016\/j.tranon.2025.102441_bib0039","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1038\/emm.2016.55","article-title":"Genetic-pathologic characterization of myeloproliferative neoplasms","volume":"48","author":"Kim","year":"2016","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.tranon.2025.102441_bib0040","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bjh.17375","article-title":"Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre","volume":"193","author":"Deschamps","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"3\u20134","key":"10.1016\/j.tranon.2025.102441_bib0041","first-page":"148","article-title":"Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders","volume":"36","author":"Marchetti","year":"2008","journal-title":"Pathophysiol. Haemost. Thromb."},{"issue":"5","key":"10.1016\/j.tranon.2025.102441_bib0042","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2025.102441_bib0043","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.6004\/jnccn.2020.7557","article-title":"A practical guide for using myelofibrosis prognostic models in the clinic","volume":"18","author":"How","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"issue":"16","key":"10.1016\/j.tranon.2025.102441_bib0044","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2025.102441_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2022.102175","article-title":"Classic myeloproliferative neoplasms in Singapore: a population-based study on incidence, trends, and survival from 1968 to 2017","volume":"79","author":"Htun","year":"2022","journal-title":"Cancer Epidemiol."},{"issue":"9","key":"10.1016\/j.tranon.2025.102441_bib0046","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.tranon.2025.102441_bib0047","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.tranon.2025.102441_bib0048","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced International prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2025.102441_bib0049","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3390\/ijms23063206","article-title":"Thromboinflammation in myeloproliferative neoplasms (MPN)-A puzzle still to Be solved","volume":"23","author":"Bhuria","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.tranon.2025.102441_bib0050","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.3390\/cancers15133331","article-title":"Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments","volume":"15","author":"Chifotides","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.tranon.2025.102441_bib0051","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jclinpath-2017-204829","article-title":"The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis","volume":"71","author":"Kuo","year":"2018","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102441_bib0052","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12967-018-1729-7","article-title":"The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms","volume":"16","author":"Greenfield","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tranon.2025.102441_bib0053","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2147\/OTT.S31916","article-title":"Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis","volume":"8","author":"Barosi","year":"2015","journal-title":"OncoTargets Ther."},{"issue":"9","key":"10.1016\/j.tranon.2025.102441_bib0054","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.tranon.2025.102441_bib0055","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.tranon.2025.102441_bib0056","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"issue":"13","key":"10.1016\/j.tranon.2025.102441_bib0057","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/cncr.34195","article-title":"Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance\/intolerance to hydroxyurea","volume":"128","author":"Alvarez-Larr\u00e1n","year":"2022","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.tranon.2025.102441_bib0058","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1038\/s41375-018-0147-4","article-title":"NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome","volume":"32","author":"Eisfeld","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.tranon.2025.102441_bib0059","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.leu.2404033","article-title":"Nfl gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways","volume":"20","author":"Yin","year":"2006","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.tranon.2025.102441_bib0060","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.tranon.2025.102441_bib0061","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D Mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332500172X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332500172X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:30:45Z","timestamp":1778833845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193652332500172X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":61,"alternative-id":["S193652332500172X"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102441","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}],"article-number":"102441"}}